NCT06088290 2026-04-17
SaLuDo
PharmaMar
Phase 3 Recruiting
Clinical Trials
7 trialsNCT07155174 2026-04-14
SEZanne
AbbVie
Phase 2 Recruiting
NCT05099666 2026-04-13
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT07328425 2026-04-03
ISG-TULIPS
Italian Sarcoma Group
Phase 2 Recruiting
NCT04607954 2026-03-31
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT05918640 2026-03-31
LiFFT
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT05578326 2026-03-30
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting